drugset
Drugs / Dendritic Cell Therapy
last change Sep 2022 re-read 3 minutes ago

Dendritic Cell Therapy

Cell therapy

Developed for
chronic lymphocytic leukemia/small lymphocytic lymphoma · follicular lymphoma · mantle cell lymphoma · marginal zone lymphoma · melanoma · primary mediastinal large B-cell lymphoma · T-cell non-Hodgkin lymphoma
Investigated by
Mayo Clinic · National Cancer Institute (NCI) · RIZIV · University Hospital Brussels

Trials 2

today NCT03035331 · Ph 1/2 NCT01676779 · Ph 2
201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT03035331 Aug 2017 → Jan 2022 T-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma +2 Mayo Clinic Completed No outcome recorded
Phase 21 trial
Phase 2 NCT01676779 Oct 2012 → Sep 2015 melanoma University Hospital Brussels Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Dendritic cell therapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT01676779 ↗
1

NCT03035331 ↗
Modality Cell therapy “mRNA Electroporated Autologous Dendritic Cells” NCT01676779 ↗
Route Intravenous “Dendritic cell therapy IV and ID” NCT01676779 ↗
Route Other “Dendritic cell therapy IV and ID” NCT01676779 ↗